|Bid||315.00 x 1100|
|Ask||334.00 x 800|
|Day's Range||326.90 - 334.52|
|52 Week Range||281.89 - 529.99|
|PE Ratio (TTM)||26.94|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||374.16|
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s returnRead More...
In the first quarter, Regeneron (REGN) and Sanofi’s (SNY) Dupixent witnessed global sales of close to $131 million, of which $117 million came from US markets. Because there was an increase in the drug’s inventory levels at the end of 2017, Dupixent reported a sequential fall in revenue in the first quarter of 2018. Further, in the first year of its launch, ~83% of patients who started on Dupixent therapy chose to remain on this regimen.
Regeneron (REGN) plans to submit a supplemental biologics license application (or sBLA) to the FDA seeking approval for Eylea in diabetic retinopathy (or DR) without Diabetic Macular Edema (or DME) in late 2018. DR without DME affects almost 3.5 million people in the United States.
Regeneron (REGN) is focused on advancing Eylea in the diabetic retinal disease segment, an area with significant unmet demand due to the rising prevalence of diabetes. The drug has emerged as the leading branded anti-vascular endothelial growth factor (or anti-VEGF) therapy for Diabetic Macular Edema (or DME). In February 2015, the company declared favorable results for Eylea from the National Institutes of Health’s sponsored comparative effectiveness study involving patients suffering from DME.
In its first-quarter conference call, Regeneron (REGN) reduced the projected range for its 2018 non-GAAP (generally accepted accounting principles) selling, general, and administrative (or SG&A) expenses from its previous guidance of $1.35 billion–$1.45 billion to $1.33 billion–$1.40 billion. The company continues to anticipate higher SG&A expenses in 2018 on a YoY (year-over-year) basis due to the commercial launches of Kevzara and Dupixent and increasing commercialization expenses for Eylea. The company’s rising focus on expanding Eylea’s label in diabetic eye diseases and commercialization expenses attributable to probable FDA approvals for dupilumab in asthma indications and cemiplimab in cutaneous squamous-cell carcinoma indications may also result in higher SG&A expenses in 2018 compared to 2017.
Regeneron’s (REGN) Eylea has continued to be the leading anti-vascular endothelial growth factor (or anti-VEGF) agent for the treatment of retinal diseases in 2018. The drug was approved by the FDA in November 2011 for wet age-related macular degeneration (or wet AMD), in July 2014 for Diabetic Macular Edema (or DME), and in March 2015 for diabetic retinopathy in patients with DME. In the first quarter, Eylea reported sales of close to $1.6 billion, and its total doses administered globally since its launch reached 15 million.
On June 19, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, Solid Biosciences’ stock price hit a 52-week high of $54.84.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...
Sanofi (SASY.PA) missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche (ROG.S) to head its group research operations. Dmitri Wiederschain, head of Sanofi's immuno-oncology research, acknowledged the company had failed to capitalise on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumour cells - in the early 2010s.
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Regeneron Pharma, Inc. (NASDAQ: REGN) ("Regeneron"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=REGN as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has inked a five-year collaboration deal with Zoetis Inc. (NYSE: ZTS), which is a global animal health Company. The deal is aimed at researching the use of Regeneron's monoclonal antibody therapeutics in animals, and discover new veterinary treatments.
After falling from $393 per share early this year to a recent low of $284 per share, analysts have begun pounding the table again for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Regeneron is a biotech company known for drugs like Zaltrap, a cancer drug.
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
TARRYTOWN, N.Y. and PARSIPPANY, N.J., June 6, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Zoetis Inc. (ZTS) today announced a five-year collaboration to research the use of Regeneron's monoclonal antibody therapeutics in animals and discover new veterinary treatments. Under the terms of the agreement, Regeneron has granted Zoetis a license for its VelocImmune® antibody technology, which Zoetis will use to develop monoclonal antibodies modified for species-specific use in companion and livestock animals.
As another outbreak of Ebola claims lives in central Africa, researchers are seeing within it a rare ray of hope: a chance to find a cure. For the first time, five experimental medicines are poised to undergo a real-life clinical trial against the virus at makeshift treatment centers in remote areas of the Democratic Republic of Congo, where most of the 53 new cases originated. Hundreds of vials of drugs in development by Gilead Sciences Inc., Regeneron Pharmaceuticals Inc. and others are on their way or in place.
After reading Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced that pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC) were published today in the New England Journal of Medicine (NEJM) and presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
PARIS and TARRYTOWN, N.Y., June 4, 2018 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC). The results were also presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Regeneron Pharmaceuticals (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying. Meanwhile Lululemom (LULU) is up a strong 17% leading the Consumer Discretionary ETFs (like XLY) to near old highs. VM Ware (VMW) is up over 6% on a strong bookings quarter.
In this updated daily bar chart of REGN, below, we can see that prices have firmed up towards the still declining 50-day moving average line. The On-Balance-Volume (OBV) line has stopped declining and could easily move up to a fresh new high from the early May low. In this weekly bar chart of REGN, below, we can see that prices are below the 40-week declining moving average line.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he doesn't like what Dicks Sporting Goods Inc (NYSE: DKS ) said on its conference call about the firearms group. He thinks it's possible ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that REGN-EB3 (also known as REGN3470-3471-3479), its investigational therapy that combines three fully-human monoclonal antibodies, is being shipped to the Democratic Republic of the Congo for use in the current Ebola virus infection outbreak. REGN-EB3 is one of several investigational therapeutics evaluated for use by a panel of independent scientific experts convened by the World Health Organization (WHO) and selected for inclusion in a potential WHO-coordinated clinical trial. Regeneron's Ebola and other infectious disease programs utilize the company's proprietary VelociSuite® technologies that facilitate rapid identification, validation and development of suitable antibody candidates to address urgent public health needs by moving from preclinical to clinical research in a matter of months instead of years.